Faecal immunochemical tests can improve colonoscopy triage in patients with iron deficiency: A systematic review and meta-analysis

IF 5.5 2区 医学 Q1 HEMATOLOGY Critical reviews in oncology/hematology Pub Date : 2024-07-06 DOI:10.1016/j.critrevonc.2024.104439
Jennifer Pham , Geraldine Laven-Law , Erin L. Symonds , Molla M. Wassie , Charles Cock , Jean M. Winter
{"title":"Faecal immunochemical tests can improve colonoscopy triage in patients with iron deficiency: A systematic review and meta-analysis","authors":"Jennifer Pham ,&nbsp;Geraldine Laven-Law ,&nbsp;Erin L. Symonds ,&nbsp;Molla M. Wassie ,&nbsp;Charles Cock ,&nbsp;Jean M. Winter","doi":"10.1016/j.critrevonc.2024.104439","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Use of the faecal immunochemical test (FIT) to triage patients with iron deficiency (ID) for colonoscopy due to suspected colorectal cancer (CRC) may improve distribution of colonoscopic resources. We reviewed the diagnostic performance of FIT for detecting advanced colorectal neoplasia, including CRC and advanced pre-cancerous neoplasia (APCN), in patients with ID, with or without anaemia.</p></div><div><h3>Methods</h3><p>We performed a systematic review of three databases for studies comprising of patients with ID, with or without anaemia, completing a quantitative FIT within six months prior to colonoscopy, where test performance was compared against the reference standard colonoscopy. Random effects meta-analyses determined the diagnostic performance of FIT for advanced colorectal neoplasia.</p></div><div><h3>Results</h3><p>Nine studies were included on a total of n=1761 patients with ID, reporting FIT positivity thresholds between 4–150 µg haemoglobin/g faeces. Only one study included a non-anaemic ID (NAID) cohort. FIT detected CRC and APCN in ID patients with 90.7 % and 49.3 % sensitivity, and 81.0 % and 82.4 % specificity, respectively. FIT was 88.0 % sensitive and 83.4 % specific for CRC in patients with ID anaemia at a FIT positivity threshold of 10 µg haemoglobin/g faeces.</p></div><div><h3>Conclusions</h3><p>FIT shows high sensitivity for advanced colorectal neoplasia and may be used to triage those with ID anaemia where colonoscopic resources are limited, enabling those at higher risk of CRC to be prioritised for colonoscopy. There is a need for further research investigating the diagnostic performance of FIT in NAID patients.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"201 ","pages":"Article 104439"},"PeriodicalIF":5.5000,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824001823/pdfft?md5=ac5a5330855ecad38078ae828e6a08b6&pid=1-s2.0-S1040842824001823-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824001823","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Use of the faecal immunochemical test (FIT) to triage patients with iron deficiency (ID) for colonoscopy due to suspected colorectal cancer (CRC) may improve distribution of colonoscopic resources. We reviewed the diagnostic performance of FIT for detecting advanced colorectal neoplasia, including CRC and advanced pre-cancerous neoplasia (APCN), in patients with ID, with or without anaemia.

Methods

We performed a systematic review of three databases for studies comprising of patients with ID, with or without anaemia, completing a quantitative FIT within six months prior to colonoscopy, where test performance was compared against the reference standard colonoscopy. Random effects meta-analyses determined the diagnostic performance of FIT for advanced colorectal neoplasia.

Results

Nine studies were included on a total of n=1761 patients with ID, reporting FIT positivity thresholds between 4–150 µg haemoglobin/g faeces. Only one study included a non-anaemic ID (NAID) cohort. FIT detected CRC and APCN in ID patients with 90.7 % and 49.3 % sensitivity, and 81.0 % and 82.4 % specificity, respectively. FIT was 88.0 % sensitive and 83.4 % specific for CRC in patients with ID anaemia at a FIT positivity threshold of 10 µg haemoglobin/g faeces.

Conclusions

FIT shows high sensitivity for advanced colorectal neoplasia and may be used to triage those with ID anaemia where colonoscopic resources are limited, enabling those at higher risk of CRC to be prioritised for colonoscopy. There is a need for further research investigating the diagnostic performance of FIT in NAID patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
粪便免疫化学检验可改善铁缺乏症患者的结肠镜检查分流:系统回顾和荟萃分析。
背景:使用粪便免疫化学检验(FIT)对因怀疑患有结肠直肠癌(CRC)而进行结肠镜检查的缺铁(ID)患者进行分流可改善结肠镜检查资源的分配。我们回顾了 FIT 在检测患有或不患有贫血症的 ID 患者的晚期结直肠肿瘤(包括 CRC 和晚期癌前肿瘤 (APCN))方面的诊断性能:我们对三个数据库中的研究进行了系统性回顾,这些研究包括在结肠镜检查前六个月内完成定量 FIT 的有或无贫血症的 ID 患者,并将测试结果与参考标准结肠镜检查进行了比较。随机效应荟萃分析确定了 FIT 对晚期结直肠肿瘤的诊断效果:共纳入九项研究,涉及 1761 名 ID 患者,报告的 FIT 阳性阈值介于 4-150µg 血红蛋白/g 粪便之间。只有一项研究纳入了非贫血 ID(NAID)队列。FIT 检测出 ID 患者中的 CRC 和 APCN 的敏感性分别为 90.7% 和 49.3%,特异性分别为 81.0% 和 82.4%。在FIT阳性阈值为10微克血红蛋白/克粪便时,FIT对ID贫血患者中的CRC的敏感性为88.0%,特异性为83.4%:FIT对晚期结直肠肿瘤的灵敏度很高,可用于在结肠镜检查资源有限的情况下对ID贫血患者进行分流,使结肠癌风险较高的患者优先接受结肠镜检查。有必要进一步研究 FIT 在非内分泌性贫血患者中的诊断效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.00
自引率
3.20%
发文量
213
审稿时长
55 days
期刊介绍: Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.
期刊最新文献
Editorial Board Erratum to “Unleashing precision: A review of targeted approaches in pleural mesothelioma” [Crit. Rev. Oncol./Hematol. 203C (2024) 104481] Corrigendum to “The emerging HER2 landscape in Colorectal Cancer: The key to unveil the future treatment algorithm?” [Crit. Rev. Oncol./Hematol. 204 (2024) 104515] Corrigendum to “Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond” [Crit. Rev. Oncol./Hematol. 200C (2024) 104404] Corrigendum to “Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis” [Crit. Rev. Oncol./Hematol. 204 (2024) 104527]
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1